Skip to main content

Bellerophon Therapeutics, Inc. (BLPH)

NASDAQ: BLPH · IEX Real-Time Price · USD
2.65
-0.19 (-6.69%)
At close: Dec 3, 2021 4:00 PM
2.71
0.06 (2.26%)
After-hours:Dec 3, 2021 5:49 PM EST
Market Cap25.19M
Revenue (ttm)n/a
Net Income (ttm)-21.49M
Shares Out9.51M
EPS (ttm)-2.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume41,318
Open2.80
Previous Close2.84
Day's Range2.60 - 2.87
52-Week Range2.60 - 9.19
Beta-0.61
AnalystsBuy
Price Target22.50 (+749.1%)
Earnings DateNov 18, 2021

About BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hyp...

IndustryHealth Care Equipment & Supplies
IPO DateFeb 13, 2015
CEOFabian Tenenbaum
Employees21
Stock ExchangeNASDAQ
Ticker SymbolBLPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for BLPH stock is "Buy." The 12-month stock price forecast is 22.50, which is an increase of 749.06% from the latest price.

Price Target
$22.50
(749.06% upside)
Analyst Consensus: Buy

News

Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings e...

2 days ago - Zacks Investment Research

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results

WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

2 weeks ago - GlobeNewsWire

Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...

2 months ago - GlobeNewsWire

2 Falling Knives to Catch

Wall Street recommends buying shares of Athenex Inc. ( ATNX , Financial) and Bellerophon Therapeutics Inc. ( BLPH , Financial). This sounds quite surprising as these two equities have performed poorly o...

Other symbols:ATNX
4 months ago - GuruFocus

Why Entera Bio, Orphazyme, Bellerophon Are Moving Today

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.

Other symbols:ENTXORPH
5 months ago - Benzinga

8 Hot Biotech Penny Stocks For Your July 2021 Watch List

Current & Former Penny Stocks To Watch Before July The post 8 Hot Biotech Penny Stocks For Your July 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:ENTXGTBPOCGNORPH
5 months ago - PennyStocks

Bellerophon to Present at the Jefferies Virtual Healthcare Conference

WARREN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments f...

6 months ago - GlobeNewsWire

Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors

Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board Dr. Amin Has Served as an Independent Director Since 2...

6 months ago - GlobeNewsWire

Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results

WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments f...

6 months ago - GlobeNewsWire

Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...

8 months ago - GlobeNewsWire

Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

11 months ago - GlobeNewsWire

Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treat...

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatmen...

WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference

WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates

Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.44% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...

1 year ago - Zacks Investment Research

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results

WARREN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial ...

WARREN, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

1 year ago - GlobeNewsWire

Bellerophon to Present at Two September Investor Conferences

WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatmen...

1 year ago - GlobeNewsWire

Bellerophon Appoints Cardiopulmonary Disease Expert Wassim Fares, M.D., MSCR, as Chief Medical Officer

WARREN, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatment...

1 year ago - GlobeNewsWire

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results

WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatment...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Partici...

Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to Placebo

1 year ago - GlobeNewsWire

Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide ...

Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States Initiation of the COViNOX Study Foll...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes

WARREN, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infecti...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered...

WARREN, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the closing of its previously announced public offering an...

1 year ago - GlobeNewsWire

Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering

WARREN, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of 3,076,923 sha...

1 year ago - GlobeNewsWire